Intramuscular, SubcutaneousActive immunisation against influenzaAdult: As inactivated or recombinant influenza vaccine: 0.5 mL for 1 dose via IM inj (preferably in the deltoid muscle) or deep SC inj. Vaccine content, route of administration and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: As inactivated influenza vaccine: 6-35 months 0.25 mL or 0.5 mL; ≥36 months 0.5 mL. In patients 6 months to <9 years of age who have not been previously vaccinated against influenza, give a 2nd dose after at least 4 weeks. Doses are given via IM inj in the anterolateral aspect of the thigh (young children) or deltoid muscle of the upper arm (older children) or deep SC inj. Vaccine content, route of administration, approved ages and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
NasalActive immunisation against influenzaAdult: As live attenuated influenza vaccine: ≤49 years 0.2 mL for 1 dose, to be given as 0.1 mL per nostril. Vaccine content, approved ages and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: As live attenuated influenza vaccine: 2-17 years 0.2 mL, to be given as 0.1 mL per nostril. In patients <9 years of age who have not been previously vaccinated against influenza, give a 2nd dose after at least 4 weeks. Vaccine content, approved ages and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
|
|
|
-
Agrippal S1
-
Fluvax
-
Inflexal V
-
Influvac
|
Hypersensitivity. Nasal: Hypersensitivity to influenza vaccine or severe allergic reaction (e.g. anaphylaxis) to any vaccine component, including egg proteins (e.g. ovalbumin); children and adolescents receiving aspirin or salicylate-containing treatment. Contraindications may vary among countries and between individual products (refer to local or specific product guidelines).
|
Patient with history of Guillain-Barre syndrome; thrombocytopenia or bleeding disorder (IM/SC); predisposition to influenza complications (e.g. CV, renal and hepatic disorders), asthma or wheezing (nasal). Immunocompromised patients may have reduced immune response to influenza vaccine. Delay vaccination in patients with acute severe febrile illness. Following vaccination with live attenuated influenza vaccine, avoid close contact with severely immunocompromised individuals (e.g. bone marrow transplant recipients needing isolation) for 1-2 weeks. Children and elderly. Pregnancy and lactation.
|
Significant: Syncope, hypersensitivity reactions, oculorespiratory syndrome.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Inj site reactions (e.g. pain, erythema, induration, ecchymosis, tenderness), chills, fatigue, fever, malaise.
Metabolism and nutrition disorders: Loss of appetite; change in eating habits (particularly in children).
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Headache; drowsiness (particularly in children).
Psychiatric disorders: Irritability (particularly in children).
Respiratory, thoracic and mediastinal disorders: Nasal congestion, rhinorrhoea (nasal).
Skin and subcutaneous tissue disorders: Sweating.
|
Nasal/Parenteral: C; Intradermal: B
|
Monitor for hypersensitivity reaction and syncope for 15 minutes after vaccination.
|
Antiviral agents may reduce the effectiveness of live attenuated influenza vaccine if administered within 48 hours before or within 2 weeks after vaccination.
Potentially Fatal: Concomitant use of live attenuated influenza vaccine and salicylates may increase the risk of Reye's syndrome.
|
Live attenuated influenza vaccine may cause positive result on the rapid influenza diagnostic test for 7 days following vaccination.
|
Description:
Mechanism of Action: Influenza vaccine promotes active immunity to seasonal influenza virus by inducing the production of specific antibodies. When given intranasally, live attenuated influenza viruses contained in the vaccine induce immunity by infecting and replicating within the cells lining the nasopharynx.
Onset: Within 2 weeks.
Duration: Approx 6-12 months.
Pharmacokinetics:
Distribution: Live attenuated vaccine: Distributed in the nasal cavity (approx 90%), stomach (approx 3%), brain (approx 2%) and lungs (0.4%).
|
Store between 2-8°C. Do not freeze. Protect from light.
|
|
|
J07BB - Influenza vaccines ; Used for active immunizations.
|
Afluria Injection, Suspension (Seqirus Pty Ltd.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. Brayfield A, Cadart C (eds). Influenza Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/12/2024. Cell-based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus Suspension for Injection in Pre-filled Syringe (Seqirus UK Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 04/12/2024. Fluarix 2024/2025 Vaccine Suspension (GlaxoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. Fluarix Tetra Suspension for Injection (GlaxoSmithKline Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 06/12/2024. Flublok Quadrivalent Northern Hemisphere Injection (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. Flublok Trivalent Northern Hemisphere Injection (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. Fluenz Nasal Spray Suspension (AstraZeneca UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 04/12/2024. FluMist Intranasal Spray (MedImmune, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. FluMist Trivalent Intranasal Vaccine Spray (AstraZeneca Hong Kong Limited). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 04/12/2024. Fluzone Quadrivalent Northern Hemisphere Injection, Suspension (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. Fluzone Trivalent Northern Hemisphere Injection, Suspension (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/12/2024. Influenza Virus Vaccine (Inactivated). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/12/2024. Influenza Virus Vaccine (Live/Attenuated). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/12/2024. Influenza Virus Vaccine (Recombinant). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/12/2024. Influvac Suspension for Injection (Abbott Laboratories [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 06/12/2024. Joint Formulary Committee. Influenza Vaccine (Inactivated). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/12/2024. Joint Formulary Committee. Influenza Vaccine (Live). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/12/2024. Seqirus (NZ) Ltd. Afluria Quad/Afluria Quad Junior Suspension for Injection data sheet 19 October 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 04/12/2024. Seqirus (NZ) Ltd. Fluad Quad Suspension for Injection data sheet 19 October 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 04/12/2024. Supemtek Solution for Injection in Pre-filled Syringe (Aventis Pharma Limited Trading as: Sanofi Pasteur). MHRA. https://products.mhra.gov.uk. Accessed 04/12/2024.
|
Sign Out
